NEWS
Lipum to participate in upcoming industry meetings
News: Umeå, 9 August 2022. Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming conferences.
Read moreLipum has recruited Helena Bergström as Chief Medical Officer
News: Umeå, 8 July, 2022. Lipum (publ) is preparing for the start of its first in human phase 1 clinical trial and the team is…
Read moreLipum initiates collaboration with Pelago Bioscience
News: Umeå, 13 May 2022. Lipum AB (publ) has started a collaboration with Pelago Bioscience AB to strengthen the bioanalytical development for pre-clinical and clinical…
Read moreBiostock: RA patients in great need of new treatment options
Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The changes in the market, and…
Read moreLipum abstract accepted for EULAR 2022
News: Umeå, 7 April 2022. Lipum (publ) reports that the abstract entitled “A Novel Target for Treatment of Inflammatory Joint Diseases” has been selected for…
Read moreLipum recruits scientist
News: Umeå, 2 February, 2022. Lipum (publ) recruits Dr. Fredrik Seijsing to strengthen the preclinical development of SOL-116.
Read moreLipum and the Scientific Advisory Board meet for the annual workshop
News: Umeå, 22 October 2021. Next week Lipums (publ) annual workshop with the Scientific Advisory Board will take place in Stockholm.
Read moreBiostock: October 12th is World Arthritis Day
World Arthritis Day (https://www.eular.org/world_arthritis_day.cfm) was established in 1996 and is intended to draw attention to and increase knowledge of rheumatic diseases among healthcare providers, decision-makersand the general…
Read more